Telix reports Q2 revenue of US$247m
July 21, 2026 | 10:44
Telix Pharmaceuticals reported US$247 million in second-quarter revenue for the period ended 30 June 2026, providing a market update on commercial performance and pipeline progress across its radiopharmaceutical portfolio.
Mobile Version